{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:13:21Z","timestamp":1777630401810,"version":"3.51.4"},"reference-count":188,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>\n                    Poly(ADP-ribose) polymerase (PARP) inhibitors constitute the inaugural targeted therapy shown to enhance the prognosis of individuals with hereditary tumors, initially utilized in the management of patients with germline\n                    <jats:italic>BRCA1\/2-<\/jats:italic>\n                    associated breast cancer. With ongoing research, PARP inhibitors (PARPi) are currently under extensive investigation for their applicability across a spectrum of diseases, encompassing oncology, cardiovascular diseases, and cerebrovascular diseases. This narrative review provides a comprehensive synthesis of the biological rationale, existing evidence, recent advancements, and prospective future directions of PARPi in the treatment of cancers, cardiovascular diseases, and cerebrovascular disorders. We provide a comprehensive overview of the recent advancements, advantages, and limitations associated with both clinically approved and investigational PARPi. Beyond their application in oncology, PARPi demonstrate significant potential in other therapeutic domains, including cardiovascular diseases. As our comprehension of the biological functions of PARP and its molecular mechanisms advances, it is anticipated that the therapeutic applications of these inhibitors will broaden considerably. Future research endeavors should prioritize the identification of predictive biomarkers across various diseases and the development of strategies to circumvent drug resistance. Consequently, the integration of fundamental and clinical research on PARPi across diverse diseases is essential to establish a foundational framework for clinical translation.\n                  <\/jats:p>","DOI":"10.7717\/peerj.20842","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T08:45:29Z","timestamp":1771577129000},"page":"e20842","source":"Crossref","is-referenced-by-count":1,"title":["Poly(ADP-ribose) polymerase (PARP) inhibitors in cardiovascular, and cerebrovascular diseases: mechanisms, current trends and challenge for clinical translation"],"prefix":"10.7717","volume":"14","author":[{"given":"Jinlin","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfangfei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4443","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"issue":"3","key":"10.7717\/peerj.20842\/ref-1","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.cardiores.2006.11.027","article-title":"The role of poly(ADP-ribose) polymerase (PARP) in the autonomous proliferative response of endothelial cells to hypoxia","volume":"73","author":"Abdallah","year":"2007","journal-title":"Cardiovascular Research"},{"key":"10.7717\/peerj.20842\/ref-2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3390\/brainsci11020249","article-title":"5-aminoisoquinolinone, a PARP-1 inhibitor, ameliorates immune abnormalities through upregulation of anti-inflammatory and downregulation of inflammatory parameters in T cells of BTBR mouse model of autism","volume":"11","author":"Alhosaini","year":"2021","journal-title":"Brain Sciences"},{"issue":"12","key":"10.7717\/peerj.20842\/ref-3","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1158\/1535-7163.MCT-11-0356","article-title":"The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice","volume":"10","author":"Ali","year":"2011","journal-title":"Molecular Cancer Therapeutics"},{"issue":"53","key":"10.7717\/peerj.20842\/ref-4","doi-asserted-by":"publisher","first-page":"55117","DOI":"10.1074\/jbc.m404524200","article-title":"Involvement of poly(ADP-ribose) polymerase-1 and XRCC1\/DNA ligase III in an alternative route for DNA double-strand breaks rejoining","volume":"279","author":"Audebert","year":"2004","journal-title":"The Journal of Biological Chemistry"},{"issue":"3","key":"10.7717\/peerj.20842\/ref-5","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.ajpath.2010.12.004","article-title":"Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases","volume":"178","author":"Ba","year":"2011","journal-title":"The American Journal of Pathology"},{"issue":"49","key":"10.7717\/peerj.20842\/ref-6","doi-asserted-by":"publisher","first-page":"6910","DOI":"10.1038\/sj.onc.1203238","article-title":"Control of apoptosis by Rel\/NF-kappaB transcription factors","volume":"18","author":"Barkett","year":"1999","journal-title":"Oncogene"},{"issue":"3","key":"10.7717\/peerj.20842\/ref-7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/FJC.0b013e3181855cef","article-title":"Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure","volume":"52","author":"Bartha","year":"2008","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"3","key":"10.7717\/peerj.20842\/ref-8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/cvr\/cvp144","article-title":"PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats","volume":"83","author":"Bartha","year":"2009","journal-title":"Cardiovascular Research"},{"issue":"1","key":"10.7717\/peerj.20842\/ref-9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/s0006-8993(03)03362-6","article-title":"Deleterious poly(ADP-ribose)polymerase-1 pathway activation in traumatic brain injury in rat","volume":"989","author":"Besson","year":"2003","journal-title":"Brain Research"},{"issue":"1","key":"10.7717\/peerj.20842\/ref-10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jamcollsurg.2006.04.004","article-title":"Poly adenosine diphosphate-ribose polymerase inhibitor PJ34 abolishes systemic proinflammatory responses to thoracic aortic ischemia and reperfusion","volume":"203","author":"Black","year":"2006","journal-title":"Journal of the American College of Surgeons"},{"issue":"6","key":"10.7717\/peerj.20842\/ref-11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/15384047.2018.1436024","article-title":"The irreversible ERBB1\/2\/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells","volume":"19","author":"Booth","year":"2018","journal-title":"Cancer Biology & Therapy"},{"issue":"1","key":"10.7717\/peerj.20842\/ref-12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1054\/bjoc.2000.1555","article-title":"Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro","volume":"84","author":"Bowman","year":"2001","journal-title":"British Journal of Cancer"},{"issue":"7035","key":"10.7717\/peerj.20842\/ref-13","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"12","key":"10.7717\/peerj.20842\/ref-14","doi-asserted-by":"publisher","first-page":"107508","DOI":"10.1016\/j.phrs.2024.107508","article-title":"New TIPARP inhibitor rescues mitochondrial function and brain injury in ischemic stroke","volume":"210","author":"Cai","year":"2024","journal-title":"Pharmacological Research"},{"key":"10.7717\/peerj.20842\/ref-15","first-page":"2711","article-title":"Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies","volume":"9","author":"Calabrese","year":"2003","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"6","key":"10.7717\/peerj.20842\/ref-16","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/jcb.20385","article-title":"Establishment of an immortalized PARP-1-\/- murine endothelial cell line: a new tool to study PARP-1 mediated endothelial cell dysfunction","volume":"94","author":"Carrillo","year":"2005","journal-title":"Journal of Cellular Biochemistry"},{"issue":"1","key":"10.7717\/peerj.20842\/ref-17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.yjmcc.2025.07.015","article-title":"Anti-cancer agent Olaparib ameliorates doxorubicin-induced cardiotoxicity in vitro and in vivo","volume":"206","author":"Chen","year":"2025","journal-title":"Journal of Molecular and Cellular Cardiology"},{"issue":"3","key":"10.7717\/peerj.20842\/ref-18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/tri.13809","article-title":"PJ34, a PARP1 inhibitor, attenuates acute allograft rejection after murine heart transplantation via regulating the CD4 T lymphocyte response","volume":"34","author":"Chen","year":"2021","journal-title":"Transplant International: Official Journal of the European Society for Organ Transplantation"},{"issue":"19","key":"10.7717\/peerj.20842\/ref-19","doi-asserted-by":"publisher","first-page":"10794","DOI":"10.1073\/pnas.1934713100","article-title":"Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice","volume":"100","author":"Cheng","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.7717\/peerj.20842\/ref-20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1423-0127-19-29","article-title":"Poly (ADP-ribose) polymerase plays an important role in intermittent hypoxia-induced cell death in rat cerebellar granule cells","volume":"19","author":"Chiu","year":"2012","journal-title":"Journal of Biomedical Science"},{"issue":"1","key":"10.7717\/peerj.20842\/ref-21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.phrs.2006.10.005","article-title":"Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines","volume":"55","author":"Cimmino","year":"2007","journal-title":"Pharmacological Research"},{"key":"10.7717\/peerj.20842\/ref-22","doi-asserted-by":"publisher","first-page":"115587","DOI":"10.1016\/j.ejca.2025.115587","article-title":"Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: final overall survival and disease-related symptoms results","volume":"225","author":"Coleman","year":"2025","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.7717\/peerj.20842\/ref-23","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/s0014-4886(03)00367-4","article-title":"3-Aminobenzamide reduces brain infarction and neutrophil infiltration after transient focal cerebral ischemia in mice","volume":"184","author":"Couturier","year":"2003","journal-title":"Experimental Neurology"},{"issue":"9","key":"10.7717\/peerj.20842\/ref-24","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1016\/j.bbagen.2015.05.014","article-title":"Identification and mechanism of action analysis of the new PARP-1 inhibitor 2\u2032\u2032-hydroxygenkwanol A","volume":"1850","author":"Dal Piaz","year":"2015","journal-title":"Biochimica et Biophysica Acta"},{"issue":"4","key":"10.7717\/peerj.20842\/ref-25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1023\/b:jobb.0000041755.22613.8d","article-title":"Deadly conversations: nuclear-mitochondrial cross-talk","volume":"36","author":"Dawson","year":"2004","journal-title":"Journal of Bioenergetics and Biomembranes"},{"issue":"8","key":"10.7717\/peerj.20842\/ref-26","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.4161\/cc.10.8.15273","article-title":"Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations","volume":"10","author":"Dedes","year":"2011","journal-title":"Cell Cycle"},{"issue":"7","key":"10.7717\/peerj.20842\/ref-27","doi-asserted-by":"publisher","first-page":"e102148","DOI":"10.1371\/journal.pone.0102148","article-title":"PARP-inhibitor treatment prevents hypertension induced cardiac remodeling by favorable modulation of heat shock proteins, Akt-1\/GSK-3\u03b2 and several PKC isoforms","volume":"9","author":"Deres","year":"2014","journal-title":"PLOS ONE"},{"issue":"21","key":"10.7717\/peerj.20842\/ref-28","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1161\/CIRCULATIONAHA.116.026099","article-title":"Nicotinamide riboside preserves cardiac function in a mouse model of dilated cardiomyopathy","volume":"137","author":"Diguet","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.7717\/peerj.20842\/ref-29","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/s0006-8993(01)02852-9","article-title":"Long-term neuroprotective effect of inhibiting poly(ADP-ribose) polymerase in rats with middle cerebral artery occlusion using a behavioral assessment","volume":"915","author":"Ding","year":"2001","journal-title":"Brain Research"},{"issue":"5","key":"10.7717\/peerj.20842\/ref-30","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"10.7717\/peerj.20842\/ref-31","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s10549-011-1441-2","article-title":"PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy","volume":"127","author":"Domagala","year":"2011","journal-title":"Breast Cancer Research and Treatment"},{"issue":"20","key":"10.7717\/peerj.20842\/ref-32","doi-asserted-by":"publisher","first-page":"18426","DOI":"10.1074\/jbc.m301295200","article-title":"Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD+ depletion and cell death induced by oxidative stress","volume":"278","author":"Du","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"issue":"12","key":"10.7717\/peerj.20842\/ref-33","doi-asserted-by":"publisher","first-page":"9156","DOI":"10.1007\/s12035-018-1063-3","article-title":"Improved reperfusion and vasculoprotection by the Poly(ADP-Ribose)Polymerase inhibitor PJ34 after stroke and thrombolysis in mice","volume":"55","author":"El Amki","year":"2018","journal-title":"Molecular Neurobiology"},{"issue":"2","key":"10.7717\/peerj.20842\/ref-34","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/1541-7786.Mcr-07-0377","article-title":"Poly(ADP-ribose) polymerase 1 promotes tumor cell survival by coactivating hypoxia-inducible factor-1-dependent gene expression","volume":"6","author":"Elser","year":"2008","journal-title":"Molecular Cancer Research: MCR"},{"issue":"6","key":"10.7717\/peerj.20842\/ref-35","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3109\/02656736.2012.695427","article-title":"Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies","volume":"28","author":"Eppink","year":"2012","journal-title":"International Journal of Hyperthermia: The Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group"},{"issue":"7035","key":"10.7717\/peerj.20842\/ref-36","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.7717\/peerj.20842\/ref-37","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1007\/s00018-006-6345-7","article-title":"Protective effects of the PARP-1 inhibitor PJ34 in hypoxic-reoxygenated cardiomyoblasts","volume":"63","author":"Fiorillo","year":"2006","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.7717\/peerj.20842\/ref-38","doi-asserted-by":"publisher","first-page":"148988","DOI":"10.1016\/j.brainres.2024.148988","article-title":"Veliparib exerts protective effects in intracerebral hemorrhage mice by inhibiting the inflammatory response and accelerating hematoma resolution","volume":"1838","author":"Fu","year":"2024","journal-title":"Brain Research"},{"issue":"5","key":"10.7717\/peerj.20842\/ref-39","doi-asserted-by":"publisher","first-page":"107985","DOI":"10.1016\/j.celrep.2020.107985","article-title":"The ubiquitin ligase TRIP12 limits PARP1 trapping and constrains PARP inhibitor efficiency","volume":"32","author":"Gatti","year":"2020","journal-title":"Cell Reports"},{"issue":"3","key":"10.7717\/peerj.20842\/ref-40","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11626-021-00543-z","article-title":"Specific protein 1 inhibitor mithramycin A protects cardiomyocytes from myocardial infarction via interacting with PARP","volume":"57","author":"Geng","year":"2021","journal-title":"In Vitro Cellular & Developmental Biology Animal"},{"issue":"2","key":"10.7717\/peerj.20842\/ref-41","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1124\/jpet.104.080705","article-title":"Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and the development of bleomycin-induced lung injury","volume":"313","author":"Genovese","year":"2005","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.7717\/peerj.20842\/ref-42","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2119\/molmed.2014.00102","article-title":"Modulation of poly(ADP-ribose) polymerase-1 (PARP-1)-mediated oxidative cell injury by ring finger protein 146 (RNF146) in cardiac myocytes","volume":"20","author":"Ger\u00f6","year":"2014","journal-title":"Molecular Medicine"},{"issue":"4","key":"10.7717\/peerj.20842\/ref-43","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"10.7717\/peerj.20842\/ref-44","doi-asserted-by":"publisher","first-page":"e1071","DOI":"10.1371\/journal.pone.0001071","article-title":"Therapeutic effect of a poly(ADP-ribose) polymerase-1 inhibitor on experimental arthritis by downregulating inflammation and Th1 response","volume":"2","author":"Gonzalez-Rey","year":"2007","journal-title":"PLOS ONE"},{"issue":"13","key":"10.7717\/peerj.20842\/ref-45","doi-asserted-by":"publisher","first-page":"5389","DOI":"10.1158\/0008-5472.CAN-09-4716","article-title":"Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells","volume":"70","author":"Gottipati","year":"2010","journal-title":"Cancer Research"},{"issue":"1","key":"10.7717\/peerj.20842\/ref-46","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.phrs.2005.02.013","article-title":"Clinical perspectives of PARP inhibitors","volume":"52","author":"Graziani","year":"2005","journal-title":"Pharmacological Research"},{"issue":"6","key":"10.7717\/peerj.20842\/ref-47","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/0300-9084(96)88154-5","article-title":"The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy","volume":"77","author":"Griffin","year":"1995","journal-title":"Biochimie"},{"issue":"6","key":"10.7717\/peerj.20842\/ref-48","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/s0026-895x(24)12278-x","article-title":"Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system","volume":"59","author":"Halmosi","year":"2001","journal-title":"Molecular Pharmacology"},{"issue":"2","key":"10.7717\/peerj.20842\/ref-49","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1161\/01.str.0000250742.61241.79","article-title":"Use of a poly(ADP-ribose) polymerase inhibitor to suppress inflammation and neuronal death after cerebral ischemia-reperfusion","volume":"38","author":"Hamby","year":"2007","journal-title":"Stroke"},{"issue":"4","key":"10.7717\/peerj.20842\/ref-50","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.annonc.2024.01.003","article-title":"Longitudinal profiling identifies co-occurring BRCA1\/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer","volume":"35","author":"Harvey-Jones","year":"2024","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"issue":"46","key":"10.7717\/peerj.20842\/ref-51","doi-asserted-by":"publisher","first-page":"45145","DOI":"10.1074\/jbc.M307957200","article-title":"Transcriptional coactivation of nuclear factor-kappaB-dependent gene expression by p300 is regulated by poly(ADP)-ribose polymerase-1","volume":"278","author":"Hassa","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"issue":"13","key":"10.7717\/peerj.20842\/ref-52","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.2741\/2909","article-title":"The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases","volume":"13","author":"Hassa","year":"2008","journal-title":"Frontiers in Bioscience: A Journal and Virtual Library"},{"issue":"4","key":"10.7717\/peerj.20842\/ref-53","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","article-title":"The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings","volume":"5","author":"Helleday","year":"2011","journal-title":"Molecular Oncology"},{"issue":"1","key":"10.7717\/peerj.20842\/ref-54","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13073-024-01370-z","article-title":"The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1\/2-associated cancer models","volume":"16","author":"Herencia-Ropero","year":"2024","journal-title":"Genome Medicine"},{"issue":"5","key":"10.7717\/peerj.20842\/ref-55","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.tips.2004.03.005","article-title":"Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling","volume":"25","author":"Hong","year":"2004","journal-title":"Trends in Pharmacological Sciences"},{"issue":"21","key":"10.7717\/peerj.20842\/ref-56","doi-asserted-by":"publisher","first-page":"11688","DOI":"10.1093\/nar\/gkad848","article-title":"Rad53 regulates the lifetime of Rdh54 at homologous recombination intermediates","volume":"51","author":"Hu","year":"2023","journal-title":"Nucleic Acids Research"},{"issue":"12","key":"10.7717\/peerj.20842\/ref-57","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1158\/2159-8290.CD-13-0891","article-title":"PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair","volume":"4","author":"Hu","year":"2014","journal-title":"Cancer Discovery"},{"issue":"12","key":"10.7717\/peerj.20842\/ref-58","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.molcel.2022.02.021","article-title":"The expanding universe of PARP1-mediated molecular and therapeutic mechanisms","volume":"82","author":"Huang","year":"2022","journal-title":"Molecular Cell"},{"issue":"10","key":"10.7717\/peerj.20842\/ref-59","doi-asserted-by":"publisher","first-page":"e27123","DOI":"10.1371\/journal.pone.0027123","article-title":"Poly(ADP-ribose) polymerase 1 is indispensable for transforming growth factor-\u03b2 Induced Smad3 activation in vascular smooth muscle cell","volume":"6","author":"Huang","year":"2011","journal-title":"PLOS ONE"},{"issue":"12","key":"10.7717\/peerj.20842\/ref-60","doi-asserted-by":"publisher","first-page":"7776","DOI":"10.1093\/nar\/gku505","article-title":"PARG is dispensable for recovery from transient replicative stress but required to prevent detrimental accumulation of poly(ADP-ribose) upon prolonged replicative stress","volume":"42","author":"Illuzzi","year":"2014","journal-title":"Nucleic Acids Research"},{"key":"10.7717\/peerj.20842\/ref-61","doi-asserted-by":"publisher","first-page":"12849","DOI":"10.1038\/ncomms12849","article-title":"PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation","volume":"7","author":"Iwata","year":"2016","journal-title":"Nature Communications"},{"issue":"6","key":"10.7717\/peerj.20842\/ref-62","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/s1734-1140(09)70222-1","article-title":"Systemic administration of lipopolysaccharide impairs glutathione redox state and object recognition in male mice. The effect of PARP-1 inhibitor","volume":"47","author":"Jacewicz","year":"2009","journal-title":"Folia Neuropathologica"},{"issue":"8","key":"10.7717\/peerj.20842\/ref-63","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/bjc.2011.382","article-title":"The role of PARP in DNA repair and its therapeutic exploitation","volume":"105","author":"Javle","year":"2011","journal-title":"British Journal of Cancer"},{"key":"10.7717\/peerj.20842\/ref-64","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.2147\/CMAR.S200524","article-title":"Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer","volume":"11","author":"Jiang","year":"2019","journal-title":"Cancer Management and Research"},{"key":"10.7717\/peerj.20842\/ref-65","first-page":"173","article-title":"Effect of PARP-1 inhibitor 4-amino-1,8-naphthalimide on the on the sensitivity of adriamycin","volume":"41","author":"Jiang","year":"2012","journal-title":"Journal of Hygiene Research"},{"issue":"12","key":"10.7717\/peerj.20842\/ref-66","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.redox.2017.11.004","article-title":"DUSP1 alleviates cardiac ischemia\/reperfusion injury by suppressing the Mff-required mitochondrial fission and Bnip3-related mitophagy via the JNK pathways","volume":"14","author":"Jin","year":"2018","journal-title":"Redox Biology"},{"issue":"24","key":"10.7717\/peerj.20842\/ref-67","doi-asserted-by":"publisher","first-page":"21717","DOI":"10.1021\/acs.jmedchem.4c01725","article-title":"Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD9574): a CNS-Penetrant, PARP1-selective inhibitor","volume":"67","author":"Johannes","year":"2024","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.7717\/peerj.20842\/ref-68","first-page":"233","article-title":"Inhibitors of poly (ADP-ribose) polymerase ameliorate myocardial reperfusion injury by modulation of activator protein-1 and neutrophil infiltration","volume":"23","author":"Kaplan","year":"2005","journal-title":"Shock"},{"issue":"4","key":"10.7717\/peerj.20842\/ref-69","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/neuonc\/noae247","article-title":"Phase 2 trial of veliparib, local irradiation, and temozolomide in patients with newly diagnosed high-grade glioma: a children\u2019s oncology group study","volume":"27","author":"Karajannis","year":"2025","journal-title":"Neuro-Oncology"},{"issue":"10","key":"10.7717\/peerj.20842\/ref-70","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.cellsig.2013.06.007","article-title":"Antagonistic crosstalk between NF-\u03baB and SIRT1 in the regulation of inflammation and metabolic disorders","volume":"25","author":"Kauppinen","year":"2013","journal-title":"Cellular Signalling"},{"key":"10.7717\/peerj.20842\/ref-71","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3390\/cells8091047","article-title":"The role of PARPs in inflammation-and metabolic-related diseases: molecular mechanisms and beyond","volume":"8","author":"Ke","year":"2019","journal-title":"Cells"},{"issue":"9","key":"10.7717\/peerj.20842\/ref-72","doi-asserted-by":"publisher","first-page":"7153","DOI":"10.1007\/s12035-018-0910-6","article-title":"Early treatment with Poly(ADP-Ribose) polymerase-1 inhibitor (JPI-289) reduces infarct volume and improves long-term behavior in an animal model of ischemic stroke","volume":"55","author":"Kim","year":"2018","journal-title":"Molecular Neurobiology"},{"issue":"10","key":"10.7717\/peerj.20842\/ref-73","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.trsl.2025.04.004","article-title":"Cardioprotective effects of PARP inhibitors: a meta-analysis of animal studies","volume":"280","author":"Kim","year":"2025","journal-title":"Translational Research"},{"issue":"10","key":"10.7717\/peerj.20842\/ref-74","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1101\/gad.1309505","article-title":"BRCA1\/BARD1 inhibition of mRNA 3\u2032 processing involves targeted degradation of RNA polymerase II","volume":"19","author":"Kleiman","year":"2005","journal-title":"Genes & Development"},{"issue":"4","key":"10.7717\/peerj.20842\/ref-75","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.bcp.2005.05.036","article-title":"Critical role of PI3-kinase\/Akt activation in the PARP inhibitor induced heart function recovery during ischemia-reperfusion","volume":"71","author":"Kovacs","year":"2006","journal-title":"Biochemical Pharmacology"},{"issue":"4","key":"10.7717\/peerj.20842\/ref-76","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.freeradbiomed.2009.05.004","article-title":"Mitochondria and reactive oxygen species","volume":"47","author":"Kowaltowski","year":"2009","journal-title":"Free Radical Biology and Medicine"},{"issue":"24","key":"10.7717\/peerj.20842\/ref-77","doi-asserted-by":"publisher","first-page":"9851","DOI":"10.1073\/pnas.1101053108","article-title":"Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition","volume":"108","author":"Krawczyk","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.7717\/peerj.20842\/ref-78","doi-asserted-by":"publisher","first-page":"115584","DOI":"10.1016\/j.ejca.2025.115584","article-title":"Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: final results of the phase 3, randomized, placebo-controlled ARIEL3 trial","volume":"225","author":"Ledermann","year":"2025","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.7717\/peerj.20842\/ref-79","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.dnarep.2008.10.002","article-title":"Recovery of deficient homologous recombination in Brca2-depleted mouse cells by wild-type Rad51 expression","volume":"8","author":"Lee","year":"2009","journal-title":"DNA Repair"},{"issue":"3","key":"10.7717\/peerj.20842\/ref-80","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/cvr\/cvn096","article-title":"Targeting the prevention of plaque rupture as a new strategy for prevention of acute arterial cardiovascular events","volume":"78","author":"Levi","year":"2008","journal-title":"Cardiovascular Research"},{"issue":"5","key":"10.7717\/peerj.20842\/ref-81","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ccr.2013.03.025","article-title":"Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation","volume":"23","author":"Li","year":"2013","journal-title":"Cancer Cell"},{"key":"10.7717\/peerj.20842\/ref-82","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.mce.2014.05.010","article-title":"AG-690\/11026014, a novel PARP-1 inhibitor, protects cardiomyocytes from AngII-induced hypertrophy","volume":"392","author":"Liu","year":"2014b","journal-title":"Molecular and Cellular Endocrinology"},{"issue":"4","key":"10.7717\/peerj.20842\/ref-83","doi-asserted-by":"publisher","first-page":"107056","DOI":"10.1016\/j.phrs.2023.107056","article-title":"Low-dose Olaparib improves septic cardiac function by reducing ferroptosis via accelerated mitophagy flux","volume":"200","author":"Liu","year":"2024","journal-title":"Pharmacological Research"},{"issue":"3","key":"10.7717\/peerj.20842\/ref-84","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.tibs.2024.12.013","article-title":"PARPs and ADP-ribosylation-mediated biomolecular condensates: determinants, dynamics, and disease implications","volume":"50","author":"Liu","year":"2025","journal-title":"Trends in Biochemical Sciences"},{"issue":"10","key":"10.7717\/peerj.20842\/ref-85","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1093\/nar\/gku284","article-title":"A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy","volume":"42","author":"Liu","year":"2014a","journal-title":"Nucleic Acids Research"},{"issue":"7381","key":"10.7717\/peerj.20842\/ref-86","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"issue":"3","key":"10.7717\/peerj.20842\/ref-87","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1021\/jm8013629","article-title":"Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhibitor","volume":"52","author":"Lord","year":"2009","journal-title":"Journal of Medicinal Chemistry"},{"issue":"12","key":"10.7717\/peerj.20842\/ref-88","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1016\/j.bbamcr.2016.09.019","article-title":"The poly(ADP-ribosyl)ation of FoxO3 mediated by PARP1 participates in isoproterenol-induced cardiac hypertrophy","volume":"1863","author":"Lu","year":"2016","journal-title":"Biochimica et Biophysica Acta"},{"issue":"1","key":"10.7717\/peerj.20842\/ref-89","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/s41467-024-46769-9","article-title":"Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment","volume":"15","author":"Maggiorani","year":"2024","journal-title":"Nature Communications"},{"issue":"7","key":"10.7717\/peerj.20842\/ref-90","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.bbadis.2014.03.008","article-title":"A quinazoline-derivative compound with PARP inhibitory effect suppresses hypertension-induced vascular alterations in spontaneously hypertensive rats","volume":"1842","author":"Magyar","year":"2014","journal-title":"Biochimica et Biophysica Acta"},{"issue":"12","key":"10.7717\/peerj.20842\/ref-91","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1021\/acs.molpharmaceut.1c00553","article-title":"P-Glycoprotein (ABCB1\/MDR1) controls brain penetration and intestinal disposition of the PARP1\/2 inhibitor niraparib","volume":"18","author":"Martins","year":"2021","journal-title":"Molecular Pharmaceutics"},{"key":"10.7717\/peerj.20842\/ref-92","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.brainres.2011.05.069","article-title":"MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, ameliorates ischemic brain damage in a non-human primate model","volume":"1410","author":"Matsuura","year":"2011","journal-title":"Brain Research"},{"issue":"7","key":"10.7717\/peerj.20842\/ref-93","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1161\/CIRCULATIONAHA.113.006167","article-title":"Role for DNA damage signaling in pulmonary arterial hypertension","volume":"129","author":"Meloche","year":"2014","journal-title":"Circulation"},{"issue":"1","key":"10.7717\/peerj.20842\/ref-94","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s12640-009-9049-6","article-title":"Protection against chronic hypoperfusion-induced retinal neurodegeneration by PARP inhibition via activation of PI-3-kinase Akt pathway and suppression of JNK and p38 MAP kinases","volume":"16","author":"Mester","year":"2009","journal-title":"Neurotoxicity Research"},{"issue":"4","key":"10.7717\/peerj.20842\/ref-95","doi-asserted-by":"publisher","first-page":"392","DOI":"10.2174\/1574892813666180305165256","article-title":"PARP inhibitors in ovarian cancer","volume":"13","author":"Mittica","year":"2018","journal-title":"Recent Patents on Anti-Cancer Drug Discovery"},{"issue":"2","key":"10.7717\/peerj.20842\/ref-96","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10863-009-9205-y","article-title":"Akt mediated mitochondrial protection in the heart: metabolic and survival pathways to the rescue","volume":"41","author":"Miyamoto","year":"2009","journal-title":"Journal of Bioenergetics and Biomembranes"},{"issue":"1","key":"10.7717\/peerj.20842\/ref-97","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1615\/critreveukaryotgeneexpr.2013006875","article-title":"Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases","volume":"24","author":"Morales","year":"2014","journal-title":"Critical Reviews in Eukaryotic Gene Expression"},{"issue":"2","key":"10.7717\/peerj.20842\/ref-98","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/s2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"The Lancet Haematology"},{"key":"10.7717\/peerj.20842\/ref-99","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.coph.2007.10.005","article-title":"Poly(ADP-ribose)polymerase 1 (PARP-1) and postischemic brain damage","volume":"9","author":"Moroni","year":"2008","journal-title":"Current Opinion in Pharmacology"},{"issue":"4","key":"10.7717\/peerj.20842\/ref-100","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11239-008-0230-1","article-title":"A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial","volume":"27","author":"Morrow","year":"2009","journal-title":"Journal of Thrombosis and Thrombolysis"},{"key":"10.7717\/peerj.20842\/ref-101","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/cmdc.201000536","article-title":"Biological effects of MC2050, a quinazoline-based PARP-1 inhibitor, in human neuroblastoma and EBV-positive Burkitt\u2019s lymphoma cells","volume":"6","author":"Mosca","year":"2011","journal-title":"ChemMedChem"},{"issue":"10","key":"10.7717\/peerj.20842\/ref-102","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/labinvest.3700326","article-title":"Inhibition of poly(ADP-ribose) polymerase attenuates the severity of acute pancreatitis and associated lung injury","volume":"85","author":"Mota","year":"2005","journal-title":"Laboratory Investigation; A Journal of Technical Methods and Pathology"},{"issue":"2","key":"10.7717\/peerj.20842\/ref-103","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Molecular Cancer Therapeutics"},{"issue":"21","key":"10.7717\/peerj.20842\/ref-104","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Research"},{"key":"10.7717\/peerj.20842\/ref-105","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.neuropharm.2012.04.014","article-title":"Unusual increase in lumbar network excitability of the rat spinal cord evoked by the PARP-1 inhibitor PJ-34 through inhibition of glutamate uptake","volume":"63","author":"Nasrabady","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.7717\/peerj.20842\/ref-106","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3390\/ijms21062159","article-title":"Molecular mechanisms of PARP-1 inhibitor 7-methylguanine","volume":"21","author":"Nilov","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"issue":"13","key":"10.7717\/peerj.20842\/ref-107","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.intimp.2018.04.043","article-title":"Regulatory T cells increase after treatment with poly (ADP-ribose) polymerase-1 inhibitor in ischemic stroke patients","volume":"60","author":"Noh","year":"2018","journal-title":"International Immunopharmacology"},{"issue":"10","key":"10.7717\/peerj.20842\/ref-108","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","article-title":"PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells","volume":"29","author":"Noordermeer","year":"2019","journal-title":"Trends in Cell Biology"},{"issue":"3","key":"10.7717\/peerj.20842\/ref-109","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1158\/1535-7163.mct-05-0418","article-title":"Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis","volume":"5","author":"No\u00ebl","year":"2006","journal-title":"Molecular Cancer Therapeutics"},{"issue":"1","key":"10.7717\/peerj.20842\/ref-110","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/jmv.23443","article-title":"Suppressive effect of PARP-1 inhibitor on JC virus replication in vitro","volume":"85","author":"Nukuzuma","year":"2013","journal-title":"Journal of Medical Virology"},{"issue":"16","key":"10.7717\/peerj.20842\/ref-111","doi-asserted-by":"publisher","first-page":"4446","DOI":"10.1093\/emboj\/18.16.4446","article-title":"Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice","volume":"18","author":"Oliver","year":"1999","journal-title":"The EMBO Journal"},{"issue":"20","key":"10.7717\/peerj.20842\/ref-112","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.4161\/cc.22026","article-title":"Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment","volume":"11","author":"Oplustilova","year":"2012","journal-title":"Cell Cycle"},{"key":"10.7717\/peerj.20842\/ref-113","doi-asserted-by":"publisher","first-page":"118936","DOI":"10.1016\/j.lfs.2020.118936","article-title":"Mitochondrial protective effects of PARP-inhibition in hypertension-induced myocardial remodeling and in stressed cardiomyocytes","volume":"268","author":"Ordog","year":"2021","journal-title":"Life Sciences"},{"issue":"18","key":"10.7717\/peerj.20842\/ref-114","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1161\/circulationaha.106.668756","article-title":"Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death","volume":"115","author":"Oumouna-Benachour","year":"2007","journal-title":"Circulation"},{"issue":"3","key":"10.7717\/peerj.20842\/ref-115","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1124\/jpet.300.3.862","article-title":"Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure","volume":"300","author":"Pacher","year":"2002","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.7717\/peerj.20842\/ref-116","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2353\/ajpath.2008.080019","article-title":"Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease","volume":"173","author":"Pacher","year":"2008","journal-title":"The American Journal of Pathology"},{"issue":"3","key":"10.7717\/peerj.20842\/ref-117","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1527-3466.2007.00018.x","article-title":"Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors","volume":"25","author":"Pacher","year":"2007","journal-title":"Cardiovascular Drug Reviews"},{"key":"10.7717\/peerj.20842\/ref-118","doi-asserted-by":"publisher","first-page":"14338","DOI":"10.3390\/cells9102286","article-title":"Modulation of inflammasome and pyroptosis by olaparib, a PARP-1 inhibitor, in the R6\/2 mouse model of huntington\u2019s disease","volume":"9","author":"Paldino","year":"2020","journal-title":"Cells"},{"key":"10.7717\/peerj.20842\/ref-119","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1021\/acsmedchemlett.8b00569","article-title":"Discovery of stereospecific PARP-1 inhibitor isoindolinone NMS-P515","volume":"10","author":"Papeo","year":"2019","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"1","key":"10.7717\/peerj.20842\/ref-120","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1038\/s41467-018-03917-2","article-title":"Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance","volume":"9","author":"Pettitt","year":"2018","journal-title":"Nature Communications"},{"issue":"23","key":"10.7717\/peerj.20842\/ref-121","doi-asserted-by":"publisher","first-page":"7917","DOI":"10.1158\/1078-0432.CCR-08-1223","article-title":"Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors","volume":"14","author":"Plummer","year":"2008","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"7","key":"10.7717\/peerj.20842\/ref-122","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/cpdd.1539","article-title":"First-in-human phase 1 study to evaluate the clinical pharmacology properties of RBN-3143, a novel inhibitor of mono-adenosine diphosphate ribosyltransferase-PARP14","volume":"14","author":"Polasek","year":"2025","journal-title":"Clinical Pharmacology in Drug Development"},{"issue":"368","key":"10.7717\/peerj.20842\/ref-123","doi-asserted-by":"publisher","first-page":"362ps317","DOI":"10.1126\/scitranslmed.aal4973","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Science Translational Medicine"},{"issue":"24","key":"10.7717\/peerj.20842\/ref-124","doi-asserted-by":"publisher","first-page":"35618","DOI":"10.18632\/oncotarget.8343","article-title":"Poly(ADP-ribose) polymerase 1 inhibition protects cardiomyocytes from inflammation and apoptosis in diabetic cardiomyopathy","volume":"7","author":"Qin","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.7717\/peerj.20842\/ref-125","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/mnfr.201600338","article-title":"1,25(OH) D improves cardiac dysfunction, hypertrophy, and fibrosis through PARP1\/SIRT1\/mTOR-related mechanisms in type 1 diabetes","volume":"61","author":"Qu","year":"2017","journal-title":"Molecular Nutrition & Food Research"},{"issue":"12","key":"10.7717\/peerj.20842\/ref-126","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.freeradbiomed.2010.09.026","article-title":"Regulation of MKP-1 expression and MAPK activation by PARP-1 in oxidative stress: a new mechanism for the cytoplasmic effect of PARP-1 activation","volume":"49","author":"Racz","year":"2010","journal-title":"Free Radical Biology and Medicine"},{"issue":"2","key":"10.7717\/peerj.20842\/ref-127","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.bbrc.2006.09.049","article-title":"Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis","volume":"350","author":"Rajesh","year":"2006","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.7717\/peerj.20842\/ref-128","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3389\/fcvm.2020.00067","article-title":"DNA damage, an innocent bystander in atrial fibrillation and other cardiovascular diseases?","volume":"7","author":"Ramos","year":"2020","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"5","key":"10.7717\/peerj.20842\/ref-129","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1158\/1078-0432.ccr-06-2260","article-title":"Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology","volume":"13","author":"Ratnam","year":"2007","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"3","key":"10.7717\/peerj.20842\/ref-130","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/cvr\/cvz252","article-title":"Peripartum cardiomyopathy: basic mechanisms and hope for new therapies","volume":"116","author":"Ricke-Hoch","year":"2020","journal-title":"Cardiovascular Research"},{"issue":"4","key":"10.7717\/peerj.20842\/ref-131","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/med.21339","article-title":"Deciphering the insights of poly(ADP-ribosylation) in tumor progression","volume":"35","author":"Rodr\u00edguez","year":"2015","journal-title":"Medicinal Research Reviews"},{"key":"10.7717\/peerj.20842\/ref-132","doi-asserted-by":"publisher","first-page":"14338","DOI":"10.3390\/ijms232214338","article-title":"Talazoparib does not interact with ABCB1 transporter or cytochrome P450s, but modulates multidrug resistance mediated by ABCC1 and ABCG2: an in vitro and ex vivo study","volume":"23","author":"Sabet","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.7717\/peerj.20842\/ref-133","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.sjbs.2019.04.003","article-title":"Anti-oxidative or anti-inflammatory additives reduce ischemia\/reperfusions injury in an animal model of cardiopulmonary bypass","volume":"27","author":"Salameh","year":"2020","journal-title":"Saudi Journal of Biological Sciences"},{"key":"10.7717\/peerj.20842\/ref-134","doi-asserted-by":"publisher","first-page":"115268","DOI":"10.1016\/j.expneurol.2025.115268","article-title":"Fasudil mitigates diabetes-associated cognitive decline and enhances neuroprotection by suppressing NLRP3\/Caspase-1\/GSDMD signaling in a stroke mouse model","volume":"389","author":"Salman","year":"2025","journal-title":"Experimental Neurology"},{"issue":"3","key":"10.7717\/peerj.20842\/ref-135","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1124\/jpet.103.063214","article-title":"The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation","volume":"310","author":"Scott","year":"2004","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"6","key":"10.7717\/peerj.20842\/ref-136","doi-asserted-by":"publisher","first-page":"104171","DOI":"10.1016\/j.labinv.2025.104171","article-title":"Prognostic value of PARP1 and PARP2 copy number alterations in prostate cancer","volume":"105","author":"Segal\u00e9s","year":"2025","journal-title":"Laboratory Investigation; A Journal of Technical Methods and Pathology"},{"issue":"10","key":"10.7717\/peerj.20842\/ref-137","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1158\/1535-7163.MCT-11-0278","article-title":"Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft","volume":"10","author":"Senra","year":"2011","journal-title":"Molecular Cancer Therapeutics"},{"issue":"19","key":"10.7717\/peerj.20842\/ref-138","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1200\/jco-24-02834","article-title":"Overall survival and the evolving benefit-risk assessment for poly (ADP-ribose) polymerase inhibitors in advanced ovarian cancer","volume":"43","author":"Shah","year":"2025","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"8","key":"10.7717\/peerj.20842\/ref-139","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1093\/nar\/gkp100","article-title":"Oxidative stress induces degradation of mitochondrial DNA","volume":"37","author":"Shokolenko","year":"2009","journal-title":"Nucleic Acids Research"},{"issue":"18","key":"10.7717\/peerj.20842\/ref-140","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.2174\/138161211796390994","article-title":"Mechanisms and inhibitors of apoptosis in cardiovascular diseases","volume":"17","author":"Singh","year":"2011","journal-title":"Current Pharmaceutical Design"},{"issue":"13","key":"10.7717\/peerj.20842\/ref-141","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","author":"Skehan","year":"1990","journal-title":"Journal of the National Cancer Institute"},{"key":"10.7717\/peerj.20842\/ref-142","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3760\/cma.j.issn.0366-6999.20121234","article-title":"Poly (ADP-ribose) polymerase inhibitor reduces heart ischaemia\/reperfusion injury via inflammation and Akt signalling in rats","volume":"126","author":"Song","year":"2013","journal-title":"Chinese Medical Journal"},{"issue":"4","key":"10.7717\/peerj.20842\/ref-143","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/00024382-200204000-00008","article-title":"Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1-deficient mice","volume":"17","author":"Soriano","year":"2002","journal-title":"Shock"},{"issue":"8","key":"10.7717\/peerj.20842\/ref-144","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1093\/carcin\/bgs132","article-title":"PARPs and the DNA damage response","volume":"33","author":"Sousa","year":"2012","journal-title":"Carcinogenesis"},{"issue":"12","key":"10.7717\/peerj.20842\/ref-145","doi-asserted-by":"publisher","first-page":"101084","DOI":"10.1016\/j.redox.2018.101084","article-title":"ROS and the DNA damage response in cancer","volume":"25","author":"Srinivas","year":"2019","journal-title":"Redox Biology"},{"issue":"1","key":"10.7717\/peerj.20842\/ref-146","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pbb.2015.03.022","article-title":"Poly (ADP-ribose) polymerase-1 inhibitor, 3-aminobenzamide pretreatment ameliorates lipopolysaccharide-induced neurobehavioral and neurochemical anomalies in mice","volume":"133","author":"Sriram","year":"2015","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10.7717\/peerj.20842\/ref-147","doi-asserted-by":"publisher","first-page":"115472","DOI":"10.1016\/j.ejca.2025.115472","article-title":"Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following poly(ADP-ribose) polymerase inhibitor treatment for advanced-stage recurrent ovarian cancer: a retrospective cohort study in England","volume":"222","author":"Steventon","year":"2025","journal-title":"European Journal of Cancer"},{"issue":"3","key":"10.7717\/peerj.20842\/ref-148","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2174\/1570161054368553","article-title":"Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: future directions","volume":"3","author":"Szab\u00f3","year":"2005","journal-title":"Current Vascular Pharmacology"},{"issue":"2","key":"10.7717\/peerj.20842\/ref-149","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.niox.2005.06.008","article-title":"Poly(ADP-ribose) polymerase activation by reactive nitrogen species--relevance for the pathogenesis of inflammation","volume":"14","author":"Szab\u00f3","year":"2006","journal-title":"Nitric Oxide: Biology and Chemistry"},{"issue":"7","key":"10.7717\/peerj.20842\/ref-150","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1007\/s11064-016-1864-6","article-title":"Neuroprotective effects of poly(ADP-ribose)polymerase inhibitor olaparib in transient cerebral ischemia","volume":"41","author":"Teng","year":"2016","journal-title":"Neurochemical Research"},{"issue":"1","key":"10.7717\/peerj.20842\/ref-151","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.phrs.2005.02.010","article-title":"Chemopotentiation by PARP inhibitors in cancer therapy","volume":"52","author":"Tentori","year":"2005","journal-title":"Pharmacological Research"},{"issue":"2","key":"10.7717\/peerj.20842\/ref-152","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1006\/phrs.2001.0935","article-title":"Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors","volume":"45","author":"Tentori","year":"2002","journal-title":"Pharmacological Research"},{"issue":"5","key":"10.7717\/peerj.20842\/ref-153","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1172\/JCI120388","article-title":"The evolving landscape of predictive biomarkers of response to PARP inhibitors","volume":"128","author":"Thomas","year":"2018","journal-title":"The Journal of Clinical Investigation"},{"issue":"12","key":"10.7717\/peerj.20842\/ref-154","doi-asserted-by":"publisher","first-page":"e0144287","DOI":"10.1371\/journal.pone.0144287","article-title":"Poly(ADP-Ribosyl)ation affects histone acetylation and transcription","volume":"10","author":"Verdone","year":"2015","journal-title":"PLOS ONE"},{"issue":"6","key":"10.7717\/peerj.20842\/ref-155","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.mam.2013.01.007","article-title":"Poly(ADP-ribose) signaling in cell death","volume":"34","author":"Vir\u00e1g","year":"2013","journal-title":"Molecular Aspects of Medicine"},{"key":"10.7717\/peerj.20842\/ref-156","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.4049\/jimmunol.161.7.3753","article-title":"Poly(ADP-ribose) synthetase activation mediates mitochondrial injury during oxidant-induced cell death","volume":"161","author":"Vir\u00e1g","year":"1998","journal-title":"Journal of Immunology"},{"issue":"3","key":"10.7717\/peerj.20842\/ref-157","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1124\/pr.54.3.375","article-title":"The therapeutic potential of poly(ADP-ribose) polymerase inhibitors","volume":"54","author":"Vir\u00e1g","year":"2002","journal-title":"Pharmacological Reviews"},{"key":"10.7717\/peerj.20842\/ref-158","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.yexcr.2018.10.003","article-title":"PARP-1 inhibition protects the diabetic heart through activation of SIRT1-PGC-1\u03b1 axis","volume":"373","author":"Waldman","year":"2018","journal-title":"Experimental Cell Research"},{"key":"10.7717\/peerj.20842\/ref-159","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0006-8993(95)01278-8","article-title":"Traumatic neuroprotection with inhibitors of nitric oxide and ADP-ribosylation","volume":"710","author":"Wallis","year":"1996","journal-title":"Brain Research"},{"issue":"7","key":"10.7717\/peerj.20842\/ref-160","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1111\/j.1476-5381.2012.01906.x","article-title":"Contribution of PARP to endothelial dysfunction and hypertension in a rat model of pre-eclampsia","volume":"166","author":"Walsh","year":"2012","journal-title":"British Journal of Pharmacology"},{"key":"10.7717\/peerj.20842\/ref-161","doi-asserted-by":"publisher","first-page":"aad6872","DOI":"10.1126\/science.aad6872","article-title":"A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1","volume":"354","author":"Wang","year":"2016","journal-title":"Science"},{"issue":"15","key":"10.7717\/peerj.20842\/ref-162","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1016\/j.molcel.2025.07.003","article-title":"PALB2 and 53BP1 govern post-resection homologous recombination DNA repair","volume":"85","author":"Wang","year":"2025b","journal-title":"Molecular Cell"},{"issue":"2","key":"10.7717\/peerj.20842\/ref-163","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.expneurol.2009.03.020","article-title":"Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos","volume":"218","author":"Wang","year":"2009","journal-title":"Experimental Neurology"},{"key":"10.7717\/peerj.20842\/ref-164","doi-asserted-by":"publisher","first-page":"116803","DOI":"10.1016\/j.bcp.2025.116803","article-title":"Parps in immune response: potential targets for cancer immunotherapy","volume":"234","author":"Wang","year":"2025a","journal-title":"Biochemical Pharmacology"},{"issue":"5383","key":"10.7717\/peerj.20842\/ref-165","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1126\/science.281.5383.1680","article-title":"NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation","volume":"281","author":"Wang","year":"1998","journal-title":"Science"},{"issue":"21","key":"10.7717\/peerj.20842\/ref-166","doi-asserted-by":"publisher","first-page":"6170","DOI":"10.1093\/nar\/gkl840","article-title":"PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways","volume":"34","author":"Wang","year":"2006","journal-title":"Nucleic Acids Research"},{"issue":"11","key":"10.7717\/peerj.20842\/ref-167","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/s41419-018-1108-6","article-title":"PARP1 promote autophagy in cardiomyocytes via modulating FoxO3a transcription","volume":"9","author":"Wang","year":"2018a","journal-title":"Cell Death & Disease"},{"issue":"3","key":"10.7717\/peerj.20842\/ref-168","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.bbrc.2018.07.091","article-title":"PARP-1 inhibition attenuates cardiac fibrosis induced by myocardial infarction through regulating autophagy","volume":"503","author":"Wang","year":"2018b","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"5","key":"10.7717\/peerj.20842\/ref-169","doi-asserted-by":"publisher","first-page":"e1007065","DOI":"10.1371\/journal.ppat.1007065","article-title":"PARP1 depletion improves mitochondrial and heart function in Chagas disease: effects on POLG dependent mtDNA maintenance","volume":"14","author":"Wen","year":"2018","journal-title":"PLOS Pathogens"},{"issue":"11","key":"10.7717\/peerj.20842\/ref-170","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1038\/cdd.2013.111","article-title":"p53 talks to PARP: the increasing complexity of p53-induced cell death","volume":"20","author":"Wiman","year":"2013","journal-title":"Cell Death and Differentiation"},{"issue":"27","key":"10.7717\/peerj.20842\/ref-171","doi-asserted-by":"publisher","first-page":"10524","DOI":"10.1074\/jbc.TM118.000372","article-title":"Homologous recombination and the repair of DNA double-strand breaks","volume":"293","author":"Wright","year":"2018","journal-title":"The Journal of Biological Chemistry"},{"issue":"9","key":"10.7717\/peerj.20842\/ref-172","doi-asserted-by":"publisher","first-page":"9755","DOI":"10.1021\/acs.jmedchem.5c00564","article-title":"Discovery and optimization of potent and highly selective PARP14 inhibitors for the treatment of atopic dermatitis","volume":"68","author":"Wu","year":"2025","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.7717\/peerj.20842\/ref-173","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.drup.2025.101290","article-title":"The role of synthetic lethality in overcoming cancer therapy resistance: emerging paradigm and recent advances","volume":"83","author":"Xiong","year":"2025","journal-title":"Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy"},{"issue":"3","key":"10.7717\/peerj.20842\/ref-174","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/med.21300","article-title":"Poly(ADP-ribose) polymerase 1 (PARP1) in atherosclerosis: from molecular mechanisms to therapeutic implications","volume":"34","author":"Xu","year":"2014","journal-title":"Medicinal Research Reviews"},{"issue":"333","key":"10.7717\/peerj.20842\/ref-175","doi-asserted-by":"publisher","first-page":"333ra348","DOI":"10.1126\/scitranslmed.aad0623","article-title":"Cultured networks of excitatory projection neurons and inhibitory interneurons for studying human cortical neurotoxicity","volume":"8","author":"Xu","year":"2016","journal-title":"Science Translational Medicine"},{"key":"10.7717\/peerj.20842\/ref-176","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mrgentox.2015.02.006","article-title":"Chromosomal damage and micronucleus induction by MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor: evidence for a non-DNA-reactive mode of action","volume":"782","author":"Yamamura","year":"2015","journal-title":"Mutation Research\/Genetic Toxicology and Environmental Mutagenesis"},{"issue":"1","key":"10.7717\/peerj.20842\/ref-177","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3109\/14756366.2011.642373","article-title":"Protective effect of cardioplegia with poly (ADP-ribose) polymerase-1 inhibitor against myocardial ischemia-reperfusion injury: in vitro study of isolated rat heart model","volume":"28","author":"Yamazaki","year":"2013","journal-title":"Journal of Enzyme Inhibition and Medicinal Chemistry"},{"issue":"7","key":"10.7717\/peerj.20842\/ref-178","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1161\/atvbaha.124.321682","article-title":"PARylation of POLG mediated by PARP1 accelerates ferroptosis-induced vascular calcification via activating Adora2a\/Rap1 signaling","volume":"45","author":"Yang","year":"2025a","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"10299","key":"10.7717\/peerj.20842\/ref-179","doi-asserted-by":"publisher","first-page":"217757","DOI":"10.1016\/j.canlet.2025.217757","article-title":"WDR11-DT enhances radiosensitivity via promoting PARP1 degradation and homologous recombination deficiency","volume":"625","author":"Yang","year":"2025b","journal-title":"Cancer Letters"},{"issue":"1","key":"10.7717\/peerj.20842\/ref-180","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/00024382-200013010-00011","article-title":"Effect of genetic disruption of poly (ADP-ribose) synthetase on delayed production of inflammatory mediators and delayed necrosis during myocardial ischemia-reperfusion injury","volume":"13","author":"Yang","year":"2000","journal-title":"Shock"},{"issue":"12","key":"10.7717\/peerj.20842\/ref-181","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1038\/sj.emboj.7600244","article-title":"Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase","volume":"23","author":"Yeung","year":"2004","journal-title":"The EMBO Journal"},{"issue":"48","key":"10.7717\/peerj.20842\/ref-182","doi-asserted-by":"publisher","first-page":"18314","DOI":"10.1073\/pnas.0606528103","article-title":"Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death","volume":"103","author":"Yu","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"9","key":"10.7717\/peerj.20842\/ref-183","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ejphar.2016.09.008","article-title":"PARP-1 inhibition alleviates diabetic cardiac complications in experimental animals","volume":"791","author":"Zakaria","year":"2016","journal-title":"European Journal of Pharmacology"},{"issue":"22","key":"10.7717\/peerj.20842\/ref-184","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1016\/j.neuron.2023.08.010","article-title":"NAD(+) rescues aging-induced blood-brain barrier damage via the CX43-PARP1 axis","volume":"111","author":"Zhan","year":"2023","journal-title":"Neuron"},{"key":"10.7717\/peerj.20842\/ref-185","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3390\/antiox13050525","article-title":"Luteolin alleviates cadmium-induced kidney injury by inhibiting oxidative DNA damage and repairing autophagic flux blockade in chickens","volume":"13","author":"Zhang","year":"2024","journal-title":"Antioxidants"},{"issue":"2","key":"10.7717\/peerj.20842\/ref-186","doi-asserted-by":"publisher","first-page":"H659","DOI":"10.1152\/ajpheart.00162.2004","article-title":"Attenuation of neointima formation through the inhibition of DNA repair enzyme PARP-1 in balloon-injured rat carotid artery","volume":"287","author":"Zhang","year":"2004","journal-title":"American Journal of Physiology-Heart and Circulatory Physiology"},{"issue":"1","key":"10.7717\/peerj.20842\/ref-187","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41421-023-00555-x","article-title":"BAF155 promotes cardiac hypertrophy and fibrosis through inhibition of WWP2-mediated PARP1 ubiquitination","volume":"9","author":"Zhang","year":"2023","journal-title":"Cell Discovery"},{"issue":"1","key":"10.7717\/peerj.20842\/ref-188","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1161\/01.res.83.1.85","article-title":"Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia\/reperfusion injury","volume":"83","author":"Zingarelli","year":"1998","journal-title":"Circulation Research"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/20842.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20842.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20842.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20842.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T08:45:32Z","timestamp":1771577132000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/20842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":188,"alternative-id":["10.7717\/peerj.20842"],"URL":"https:\/\/doi.org\/10.7717\/peerj.20842","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"article-number":"e20842"}}